Intermediatebiotechnology
Hemophilia Genetics
Overview
Hemophilia A (F8, 1/5000 males) and B (F9, 1/30,000 males) are X-linked recessive clotting factor deficiencies causing prolonged bleeding into joints and muscles. Queen Victoria's descendants spread it through European royalty ('the royal disease'). Treatment evolved from plasma to recombinant factors to emicizumab (bispecific antibody) and gene therapy (Hemgenix, Roctavian).
Learning objectives
- Explain X-linked recessive inheritance with pedigrees
- Distinguish hemophilia A and B
- Narrate the royal disease history
- Describe modern treatments
The genetics
F8 (hemophilia A) and F9 (B) sit on the X: males with the mutation are affected; carrier females usually asymptomatic (factor levels ~50%, enough). 50% of a carrier's sons affected, 50% of daughters carriers. ~30% of cases are de novo. Severity tracks factor level: severe <1%, moderate 1-5%, mild 5-40%.
Affected males connected through carrier females; no male-to-male transmission.
The royal disease
Queen Victoria (carrier, likely de novo) transmitted hemophilia to descendants: her son Leopold died of it; daughters carried it into Russian (Alexei Romanov), Spanish, and German royal houses. Rasputin's influence over the Tsarina partly rested on 'treating' Alexei. History pivoted on a mutation.
Alexei's hemophilia destabilized Romanov Russia: genetics as geopolitics.
Bleeding and complications
Prolonged bleeding after injury, spontaneous hemarthroses (joint damage), muscle hematomas, intracranial hemorrhage risk. Inhibitors (antibodies against infused factor) complicate ~30% of severe A. Contaminated plasma concentrates tragically infected many with HIV/HCV in the 1980s.
1980s factor concentrates spread HIV/HCV to thousands of hemophiliacs: a lasting lesson in blood safety.
Modern treatment
Recombinant factors (safe from pathogens), emicizumab (bridges IXa-X, subcutaneous prophylaxis for A), extended half-life products, and gene therapy: Hemgenix (B) and Roctavian (A) deliver functional genes via AAV. CRISPR approaches in trials.
Hemophilia treatment mirrors biotech history: each era's flagship technology applied.
Key points
- F8 (A) / F9 (B): X-linked recessive; 50% of carrier's sons affected
- Queen Victoria spread it through European royalty
- Bleeding into joints/muscles; inhibitors complicate treatment
- Recombinant factors, emicizumab, AAV gene therapy
Common misconceptions
✓ Truth: Homozygous/compound females (rare), skewed X-inactivation, or Turner (X0) females can be affected.
✓ Truth: Some carriers have low factor levels and mild bleeding: check levels, don't assume.
Practice questions
Q1. Hemophilia A is caused by deficiency of
- Factor IX
- Factor VIII
- Platelets
- Vitamin K
F8 mutations: the commoner form (1/5000 males).
Q2. A carrier female has, per son, a ___ chance of hemophilia
- 100%
- 50%
- 25%
- 0%
X-linked recessive: half her sons get the mutant X.
Q3. The 'royal disease' spread through Europe from
- Napoleon
- Queen Victoria
- Charlemagne
- Peter the Great
Victoria's carrier daughters married into continental royal houses.
Click a question to reveal the answer and explanation.
Frequently asked questions
Why no male-to-male transmission?
Fathers give sons Y, not X: X-linked traits pass father->daughter->grandson.
What are inhibitors?
Alloantibodies neutralizing infused factor VIII: the major treatment complication, bypassed by emicizumab.
How does emicizumab work?
Bispecific antibody mimicking factor VIIIa, bridging IXa and X: prophylaxis without factor infusions.